The Product coming out of Paducah from the tails, will already be at UF6, but Centrus don't enrich Uranium themselves as far as I know? They pay the Russians to do that, I don't think that will sit well with the powers to be in the US and I don't reckon ACP will be a goer? simply because of costs, who's going to pay for a plant like that?
Centrus certainly don't have the money.
GK said he was going to the non oncology area when he left, Novogen has a stable full of IP related to non oncology stuff, that already have links to the Feinstein institute. the Cancer stuff will be fine.
You are a total hyporcrite, you post BS on hotcopper all of the time, don't try and tell me where to get off you dimwit.
Obviously there is something afoot, what does Centrus have that would be of any value to Converdyn?
There is only one thing that Centrus may have that may be of value to Converdyn going forward, it all has in my opinion links to what is happening at Global Laser Enrichment, they are working on recycling used nuclear fuel, GEH has indicated that it wants to reduce it's holding in GLE, I believe it is Hitachi that wants out to concentrate on it's core business PRISM, don't be suprised if they (GEH) get the UK contarct for PRISM to get rid of the Plutonium stockpile, anyway back to Converdyn, I reckon they will pick up part of what Hitachi may be putting up for sale, Converdyn has far better synergies to GLE than Hitachi ever had, I believe what Converdyn are after is the license agreements for the supply of nuclear fuel, that is, it wont be Russia supplying fuel for LWR's, it will be GNF using GLE recycled UNF in the future, it won't be for a while but it is happening behind the scenes.
The info below is just one reference to unf recycling, there are many others that are much later but this gives you an idea of how long it has been going on for,
google An Overview of GEH Nuclear Criticality Safety Fuel Cycle Activities Lon Paulson
Midostaurin the First Targeted Therapy to Improve Survival in AML: Potentially Practice-Changing
VBCC - February 2016, Vol 7, No 1 - Emerging Therapies
The multikinase inhibitor midostaurin is the first targeted therapy to improve overall survival (OS) in patients with acute myeloid leukemia (AML) and the FLT3 mutation. Midostaurin plus standard chemotherapy improved survival compared with placebo plus chemotherapy as an upfront treatment for high-risk patients with AML and FLT3 mutations.
Patients and physicians have waited for new drugs for AML since the 1990s, so the results of the CALGB 10603/RATIFY trial were greeted with enthusiasm at ASH 2015. The study was an undertaking of the Alliance for Clinical Trials in Oncology.
It can't come fast enough, I was watching something on TV yesterday here in Oz, where the court has ruled that a six year old boy be given radiation and chemo to save his life, his parents didn't want that, they didn't want to see thier son suffer the horrific side effects from chemo and radiation treatment.
It must be hard for adults to suffer these side effects let alone kids.